Birabresib

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameBirabresib
Drug Alias NameY-803MK-8628OTX-015
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBromodomain-containing protein 4 inhibitorsBromodomain-containing protein 3 inhibitorsBromodomain-containing protein 2 inhibitors
TargetsBromodomain-containing protein 3Bromodomain-containing protein 2Bromodomain-containing protein 4
Therapy Area/IndicationsNUT midline carcinomaProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell Lung +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMitsubishi Tanabe Pharma Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOncoethix GmbhMerck Sharp & Dohme LLC
Active IndicationsN/A
Inactive IndicationsNUT midline carcinomaProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell Lung +[10] 

Other Information

ATC CodeN/A
Related LinksN/A